KAN-003 / Kanvas Biosci, UT MD Anderson Cancer Center - LARVOL DELTA

Kanvas Biosciences Secures Additional $12.5M to Advance Its Novel, Microbiome-Based Immuno-oncology Drug Candidates to IND Filing (PRNewswire) - "Kanvas Biosciences...announced it has raised $12.5 million in additional funding...The fresh capital closely follows a June 2023 round and brings Kanvas's total funding to $29.5 million. The funding will be used to further develop the company's spatial biology platform and advance two novel therapeutics in its Immuno-oncology Program, KAN-001 and KAN-003 — KAN-001 to an Investigational New Drug (IND) filing in 2025....Kanvas is collaborating with The University of Texas MD Anderson Cancer Center and its Platform for Innovative Microbiome and Translational Research (PRIME-TR) to conduct additional preclinical studies for KAN-001 to optimize the drug's formulation and prepare it for an IND filing in 2025, preparatory to recruiting the first patients for a clinical trial the same year."

Financing • IND • Licensing / partnership • Oncology • Solid Tumor